Sinovac Biotech logo

SVA - Sinovac Biotech News Story

$6.47 0.0  0.0%

Last Trade - 22/02/19

Sector
Healthcare
Size
Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £192.8m
Position in Universe th / 6825

UPDATE 1-Brazil approves Pfizer's COVID-19 shot, but has none to use

Tue 23rd February, 2021 1:33pm
(Adds details on contract dispute)
    SAO PAULO, Feb 23 (Reuters) - Brazil has fully approved a
COVID-19 vaccine developed by Pfizer Inc  PFE.N  and BioNTech SE
 22UAy.F , health regulator Anvisa said on Tuesday, although it
remains to be seen if Brasilia and Pfizer can end a dispute and
agree a supply deal.
    The Pfizer/BioNTech shot is the first vaccine against the
novel coronavirus to receive full approval in Brazil, Anvisa
said. Other vaccines developed by AstraZeneca  AZN.L  and
China's Sinovac Biotech Ltd  SVA.O , have only been approved for
emergency use so far. 
    The approval is good news for a country whose immunization
campaign has been plagued by delays and political squabbling.
However, it is unclear whether the definitive approval of the
vaccine will pave the way for a supply deal of a highly
effective shot that is already being applied globally.
    President Jair Bolsonaro has criticized the terms of a deal
proposed by Pfizer, saying it is overly onerous on Brazil as it
exempts the U.S. firm from potential liability for unforeseen
problems. Pfizer has said other countries, including neighbors
in Latin America, have agreed to the terms.
    Pfizer and Brazil's Health Ministry did not immediately
respond to a request for comment. 

 (Reporting by Eduardo Simoes. Writing by Gabriel Stargardter.
Editing by Brad Haynes and Mark Potter)
 ((Gabriel.Stargardter@thomsonreuters.com; +55 21998116099;
Reuters Messaging:
gabriel.stargardter.thomsonreuters.com@reuters.net))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.